Quitting X. No room in my life for toxicity.

The FLOW trial was stopped early due to clear benefits for using semaglutide to reduce progression of kidney disease and cardiovascular death in people with #T2D at risk for progressive diabetic kidney disease @US_FDA @novonordiskus

A special happy birthday to Professor Michael Nauck, a leader in the translational biology of gut hormones and related metabolic therapies #diabetes #Obesity @EASDnews @DiabResearch

More on FLOW trial and CV outcomes #kidneywk 🎤Presented by Richard E. Pratley @RpratleyMD Semaglutide reduced the risk of all-cause death and CV death

overFLOWing evidence for semaglutide in CKD: here come the heart failure data 😎 Thank you @RpratleyMD @KatherineTuttl8 @P_Rossing @VladoPerkovic and the other FLOW investigators! https://t.co/FTfhS2bqSz

Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chron... https://t.co/AUhIPS78jh Just presented at #ESC and published in #JACC - semaglutide decreased risk of heart failure and CV death by 27% in the FLOW trial in T2D and CVD.

Excited to be presenting the results of the FLOW trial - first dedicated CKD trial with a GLP-1 receptor agonist - at the ERA in Stockholm.

Join us for a webinar on May 7, 4:00 p.m. ET: "Beyond Basics: Unraveling Challenging Type 2 Diabetes Cases." Learn advanced treatment therapies and decision-making from experts. Register now: https://t.co/BE2pa6ySdG

Support my JDRF One Walk

Proudly presenting Part II of our #SpecialIssue on Preventing Metabolic Disease! “Variability is the law of life, and as no two faces are the same, so no two bodies are alike.”—Sir William Osler, 1903. Covert Art: Julia Saxton Noone and Mucinski et al. discuss individual response

📰Pancreatic #diabetes may be nearly as common as type 1 diabetes, but much less is known about the condition. Learn more about pancreatic diabetes in this Healio Exclusive from @EndocrineToday: 👇 @RPratleyMD https://t.co/KhPnQzlvye

Real world data in millions of PPL with metabolic liver disease and #T2D reveals GLP-1RAs are associated with lower incidences of adverse CVEs and all-cause mortality #CVD #heartdisase @DiabetologiaJnl https://t.co/F5XvwNpOJU

#WCIRDC23 👏👏👏 to @YHandelsmanMD & the program committee for another superb @WCIRDC! Full house every day! 🙏🏻 to all of the supporting companies! @Amgen @BayerPharma @AstraZenecaUS @boehringerus @EliLillyandCo @LexPharma @EsperionInc @GoHealio @MIOAmerica @HeartinDiabetes

Wrapping up Day of of Clinical Pathways in #T2D Care: Overcoming Inertia, Implementing Innovation Dr. Tim Garvey, @RpratleyMD, @RothbergAmy and Michele Tedder

In the dynamic ebb and flow of the GLP-1 space beyond #T2D #obesity does @EliLillyandCo have the edge in portfolio depth, whereas @novonordisk leads in the breadth of expanding the evidence base for semaglutide? Discuss

Previous speculation that GI side effects of GLP1-RAs may lead to reduced food intake & associated weight loss Our analysis shows weight reduction with tirzepatide (from SURPASS studies) is independent of reported side effects https://t.co/bFkZHBeL32

Big news: the FLOW trial of semaglutide for kidney protection in CKD stopped at pre-planned interim analysis. Trial now to close out and results will be available in first half of 2024. #FLOWtrial #semaglutide #ozempic

Exciting news for #DKD. Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis

Can’t tell if Penny is excited about the new mobile groomer or just happy she has had lots of treats #GoldenPenny

Harpreet Bajaj reviewing #diabetes #remission @ #diabetesdialog2023 hosted by the Barbara Davis Center for Diabetes - a new pathway for early #T2D